Skip to NavigationSkip to content

Business Services

CPhI: Festival of Pharma

Gilead agrees to pay $97 million to settle Medicare kickbacks case

Photo by Mike Mozart

Gilead has agreed to pay $97 million to resolve claims from the US Government that it used an independent charity to pay illegal kickbacks to cover Medicare patients’ upfront costs for its drug Letairis. 

Independent review finds no evidence of insider trading from Kodak executives before US Government pharma deal

Photo by El Grafo

Kodak has been cleared of insider trading by an independent review after one of its top executives bought shares before a stock surge following the news of a loan from the US Government to produce pharmaceutical ingredients. 

Oncology research in the age of COVID-19

Published on 14/09/20 at 12:39pm

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive COVID-19 pandemic.

Targazyme snaps up new CEO

Published on: 11/09/20

Experienced industry executive James Caggiano has been named as the new head of Californian biotech Targazyme, who will take up the mantle of the company’s new Chief Executive Officer.  

Caggiano has been working in the industry for almost three decades with particular experience in pharmaceuticals, medical devices, and immuno-oncology.'s weekly COVID-19 news round-up

The coronavirus news this week focuses on lockdowns and infections, as England is set to increase lockdown restrictions across the country after a surge in coronavirus cases and 60,000 people across Britain may have been suffering from prolonged symptoms of coronavirus months after contracting the virus.

Industry veteran Dr Steen Klysner appointed as Amarna's new CEO

Published on: 09/09/20

Amarna Therapeutics has announced the appointment of a new Chief Executive Officer (CEO), hiring industry veteran Dr Steen Klysner to the role.

FibroGen names appointment for newly created Chief Scientific Officer role

Published on: 08/09/20

FibroGen has created the new role of Chief Scientific Officer and appointed Dr Percy Carter to the position, it has emerged.

Dr Carter joins the company from Janssen, where he led over 700 employees as Global Head of Discovery Sciences in functions including Computational Sciences, Discovery Chemistry, Drug Metabolism & Pharmacokinetics, Lead Discovery, and Core Business Services. During this time, he primarily led operations to identify and refine novel small molecule, peptide, and RNA-based drug candidates.

Advaxis Chief Financial Officer resigns

Published on: 08/09/20

Molly Henderson, the Chief Financial Officer and Executive Vice President of Advaxis, has announced her resignation that will take effect at the end of September.

Henderson has resigned to pursue a new business opportunity. Kenneth A. Berlin, Advanxis’ President and Chief Executive Officer, will serve as interim CFO until a new person can be appointed to the position.

Working Life Interview: Fiona Huzarski, Vice President of Global HR, ADVANZ PHARMA

Published on 26/08/20 at 12:08pm

“Every company is different, so you have to be open-minded and receptive to the culture when joining.”

Can you briefly take us through your career journey so far? 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches